The North America Expression Vectors Market is projected to witness substantial growth from 2024 to 2035 owing to growing applications in biopharmaceutical research and development as well as the rising demand for biologics. The market size was valued at USD 492 Million in 2025 and is expected to reach USD 1,293 Million by 2035, exhibiting a CAGR of 9.2% from 2024 to 2035.
The economic impact of tariffs on "North America Expression Vectors Market".
Market Growth Drivers
Expansion of Biopharmaceutical Research: The growing adoption of expression vectors in drug discovery, vaccine development, and synthetic biology is significantly propelling the market. Major pharmaceutical firms like Thermo Fisher Scientific are investing heavily in R&D for biologics production and recombinant protein expression, which are key therapeutic modalities for chronic and rare diseases. For instance, Thermo Fisher’s newly launched Gibco™ Expi293™ Expression System Suite provides a scalable approach for high-yield protein expression, supporting biopharma drug pipelines.
Technological Advancements in Vector Design: Innovative technology enabling the development of next-generation vectors—such as CRISPR-activated and self-amplifying vectors—has increased expression efficiency and specificity. Companies like Promega Corporation are leading advancements in inducible and selectable vectors, facilitating faster and more accurate production of proteins for therapeutic research and diagnostics.
Market Trends
Rising Demand in Cell and Gene Therapy: Expression vectors are seeing surging demand in the development and manufacturing of cell and gene therapies. For example, Addgene has noted a substantial uptick in vector orders for gene therapy research in the last year. These vectors support the production of viral and non-viral platforms, contributing to the growth of the regenerative medicine landscape in North America.
Strategic Collaborations and Licenses: Companies are entering into strategic collaborations and licensing agreements to strengthen their position in the market. In late 2023, GenScript Biotech partnered with several US-based research institutions to optimize mammalian expression systems, facilitating the production of antibodies and recombinant proteins with higher yield and purity, further driving market expansion.
Market Opportunities
Emergence of Personalized Medicine: The increasing focus on individualized therapies, such as personalized cancer vaccines and targeted gene treatments, offers vast opportunities for companies developing novel and efficient expression vector systems. Firms like Lonza are expanding their offerings to include customized vector production for clinical research programs.
Growth of CRO and CDMO Services: Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) are increasingly adopting advanced expression vectors to deliver high-quality and scalable gene and protein production services to pharmaceutical companies, enhancing overall market potential.
North America Expression Vectors Market Revenue (USD Million), 2020-2035
The revenue chart for the North America Expression Vectors Market demonstrates a robust growth trajectory over the 16-year period. In 2020, the market was valued at approximately USD 285 million, witnessing a moderate annual increase up to 2025 (USD 492 million). Post-2025, the market shows accelerated growth, climbing sharply to USD 1,293 million by 2035. This surge is driven by innovative biopharmaceutical research, expansion in gene therapy, and widened adoption in vaccine development. The CAGR of 9.2% highlights the market's sustainability and innovation, with future prospects especially strong in the US and Canada.
North America Expression Vectors Market by Regions Share (%), 2025
In 2025, the United States dominates the North America Expression Vectors Market with a 76% share, attributed to its leadership in biotech research, presence of major pharmaceutical companies, and strong federal investment. Canada follows with 16%, supported by an expanding healthcare R&D infrastructure and increasing biotech startups. Mexico captures 5%, driven by growing pharma outsourcing and supportive government initiatives. Other North American regions, including Puerto Rico and Bermuda, account for the remaining 3%, indicating lower but growing adoption. This regional breakdown reflects the pivotal role of the US while highlighting growth potential in other regions.
Recent Market Developments – Last 6 Months
March 2024: Thermo Fisher Scientific launched the new Invitrogen TrueDesign CRISPR Vector Suite, enabling researchers to quickly construct and optimize custom vectors for gene editing and protein expression. This advancement accelerates timelines for drug discovery programs and supports precision biology approaches for pharma clients in North America.
April 2024: GenScript Biotech announced the expansion of its U.S. vector manufacturing facility, increasing its capacity for plasmid preparation and virus packaging. The expansion is in response to surging demand for gene therapy vectors among North American biotech startups and pharma companies. The new facility will improve scalability, efficiency, and time-to-market for therapeutic developers.
May 2024: Addgene launched a new online vector design platform in partnership with leading academic institutions. The platform offers researchers access to customizable expression vectors, streamlined licensing, and support tools for optimizing transfection and expression results, making it easier for labs to translate genetic innovations into practical biopharma applications.
Press Releases